Loading…

Single-Center Long-Term Follow-Up After Intraoperative Radiotherapy as a Boost During Breast-Conserving Surgery Using Low-Kilovoltage X-Rays

Background Intraoperative radiotherapy (IORT) during breast-conserving surgery as a boost followed by whole-breast radiotherapy is increasingly used. Methods Between February 2002 and December 2008, a total of 197 patients were treated with IORT as a boost (20 Gy, 50 kV x-rays; Intrabeam System, Car...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2010-10, Vol.17 (Suppl 3), p.352-358
Main Authors: Blank, Elena, Kraus-Tiefenbacher, Uta, Welzel, Grit, Keller, Anke, Bohrer, Markus, Sütterlin, Marc, Wenz, Frederik
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Intraoperative radiotherapy (IORT) during breast-conserving surgery as a boost followed by whole-breast radiotherapy is increasingly used. Methods Between February 2002 and December 2008, a total of 197 patients were treated with IORT as a boost (20 Gy, 50 kV x-rays; Intrabeam System, Carl Zeiss Surgical, Oberkochen, Germany) during breast-conserving surgery, followed by whole-breast radiotherapy (46–50 Gy). Systemic therapy was provided according to the St. Gallen consensus. Patients were recalled every 6–12 months for follow-up. Findings were scored according to the LENT-SOMA scale. Results Median age was 61.8 (range 30–84) years, and median follow-up was 37 (range 5–91) months. There were T1, T2, and Tx tumors in 129, 67, and 1 patients, respectively, and N0, N1, N2, and N3 disease in 144, 36, 15, and 2 patients, respectively. Until December 2009, 5 local invasive relapses, 1 local ductal carcinoma-in-situ, 1 axillary relapse, 6 secondary cancers, and 11 distant metastases were seen, resulting in a 5-year disease-free survival of 81.0% and an overall survival of 91.3%. Local relapse-free survival (invasive cancers) at 3 and 5 years was 97.0%. After a follow-up of 5 years ( n  = 58), only 8 patients (13.8%) had chronic skin toxicities, and 2 patients (3.4%) had a marked increase in density (fibrosis III), while 62.0% had no/barely palpable fibrosis 0–I. Other toxicities observed included severe pain ( n  = 4, 6.9%), retraction ( n  = 17, 29.3%), edema of the breast ( n  = 1, 1.7%), and lymphedema in general ( n  = 2, 3.4%). Conclusions After IORT as a tumor bed boost with low-kilovoltage x-rays followed by whole-breast radiotherapy, low local recurrence and chronic toxicity rates were seen after 5-year follow-up.
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-010-1265-z